

## CORRIGENDUM

# Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia

MR Kibbe, AT Hirsch, FO Mendelsohn, MG Davies, H Pham, J Saucedo, W Marston, W-B Pyun, S-K Min, BG Peterson, A Comerota, D Choi, J Ballard, RA Bartow, DW Losordo, W Sherman, V Driver and EC Perin

*Gene Therapy* (2016) 23, 399; doi:10.1038/gt.2016.9

**Correction to:** *Gene Therapy* (2016) 23, 306–312; doi:10.1038/gt.2015.110; published online 14 January 2016

Following the online publication for this article, the authors noted that the funding information provided was incomplete. The full correct funding statement should appear as follows:

Funded by ViroMed Co., Ltd, Seoul, Korea, and Reyon Pharmaceutical Co., Ltd, Seoul Korea, and supported by the Industrial Strategic Technology Development Program (grant no. 10031644, 'Clinical development of cardiovascular therapeutics (VM202) using novel hepatocyte growth factor gene in the US') funded by the Ministry of Trade, Industry & Energy (MI, Korea).